SCB-2020S / Sichuan Clover Biopharma - LARVOL DELTA

Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults (clinicaltrials.gov) - P1 | N=153 | Completed | Sponsor: Clover Biopharmaceuticals AUS Pty Ltd | Active, not recruiting ➔ Completed | Trial completion date: Sep 2023 ➔ Apr 2023 | Trial primary completion date: Sep 2023 ➔ Sep 2022

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults (clinicaltrials.gov) - P1 | N=153 | Active, not recruiting | Sponsor: Clover Biopharmaceuticals AUS Pty Ltd | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults (clinicaltrials.gov) - P1 | N=152 | Recruiting | Sponsor: Clover Biopharmaceuticals AUS Pty Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults (clinicaltrials.gov) - P1 | N=152 | Not yet recruiting | Sponsor: Clover Biopharmaceuticals AUS Pty Ltd

New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Immunogenicity and Safety of Adjuvanted SCB-2020S Vaccines in Adults (clinicaltrials.gov) - P2; N=0; Withdrawn; Sponsor: Clover Biopharmaceuticals AUS Pty Ltd; N=150 ➔ 0; Not yet recruiting ➔ Withdrawn

Clinical • Enrollment change • Trial withdrawal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Immunogenicity and Safety of Adjuvanted SCB-2020S Vaccines in Adults (clinicaltrials.gov) - P2; N=150; Not yet recruiting; Sponsor: Clover Biopharmaceuticals AUS Pty Ltd

Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases